A phase 2 study of the WEE1 inhibitor AZD1775 in <i>SETD2</i>-deficient advanced solid tumor malignancies.
Edward Maldonado(University of California, San Francisco), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Victor Ricardo Adorno Febles(NYU Langone Health), Nikolaos A. Trikalinos(University of California, San Francisco), Geoffrey I. Shapiro(Brigham and Women's Hospital), Patricia LoRusso(Yale Cancer Center), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Naoko Takebe(National Cancer Institute), Arash Rezazadeh(University of California, Irvine Medical Center), Scott A. Boerner, Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Gregor Krings(Cleveland Clinic), Mamta Parikh(UC Davis Comprehensive Cancer Center)
Cited by 3
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
|The Lancet Oncology|2011|903
Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor
|New England Journal of Medicine|2010|871